Polymarket and Kalshi list health-related prediction contracts
Regulation2 min read
Summary
Polymarket and Kalshi have begun listing contracts tied to health policy and clinical research, reportedly including markets on possible changes to US vaccine guidance. Kalshi spokesperson Dani Lever said clinical-trial and drug-approval markets may improve transparency in drug development, while Rutgers professor Lia Nower called for stronger government oversight; critics warned trading could affect trial behaviour.
Polymarket and Kalshi are reportedly offering health-related prediction contracts. The contracts include bets on whether the US Centers for Disease Control and Prevention will change its vaccine recommendations.
Kalshi spokesperson Dani Lever said markets on clinical trials and drug approvals could make drug development more transparent.
Trial participants could deliberately change their behaviour to sway results, while drugmakers could adjust trial schedules to influence predictions, critics warn. Matthew Eisenberg, a Johns Hopkins professor who chairs health policy and management, was unsurprised by the listings. He said markets on Food and Drug Administration decisions and clinical trial outcomes give people with confidential information a financial incentive. He saw a potentially greater concern in financial inducements to leak insider information than in bribery, even if platforms check users' employment during registration.
Lia Nower, professor and director of the Center for Gambling Studies at Rutgers University, said prediction markets were functionally indistinguishable from regulated gambling but remained largely unregulated. Nower called for stronger government oversight and federal action. She said the US lacks a dedicated federal gambling regulator and National Institutes of Health research centres focused specifically on gambling.
Prediction markets classify themselves as financial derivatives, placing them under federal commodities laws and CFTC oversight rather than state gambling regulations. Several states have sued the companies, arguing that their platforms operate as gambling sites.